期刊文献+

基于TCGA和GEO数据库结肠癌表观遗传预后模型构建与验证 被引量:1

Construction and validation of an epigenetic prognostic signature of colorectal cancer based on TCGA and GEO databases
下载PDF
导出
摘要 目的使用TCGA和GEO数据库构建结肠癌(colorectal cancer,CRC)表观遗传的预后模型并验证。方法首先,公共数据库下载试验组数据(TCGA-COAD,n=446)、验证组数据(GSE39582,n=561)及表观遗传基因(EpiFactors,n=720);其次,单因素Cox回归筛选TCGA、GEO预后相关的基因,与EpiFactors数据库交集得到表观遗传相关影响预后的基因(epigenetic-related genes,ERGs)并对其进行富集分析;随后,多因素Cox回归构建预后模型,绘制列线图并验证。结果本研究共筛选得到6个ERGs,并构建预后模型,预测模型ROC的AUC为0.722,1年、3年和5年的校准曲线与实际结果相吻合,提示预测能力良好。结论本研究通过公共数据库筛选出6个ERGs(LBR、SMARCD3、ZNF532、MAPKAPK3、SFPQ、SIN3B)与结肠癌预后密切相关。 Objective To identify novel epigenetic-related biomarkers in colorectal cancer(CRC).Methods The training dataset was downloaded from The Cancer Genome Atlas(TCGA-COAD,n=446),the validation dataset was downloaded from the Gene Expression Omnibus(GSE39582,n=561),epigenetic-related genes were downloaded from the EpiFactors dataset(n=720).Overall survival-related genes were screened by Univariate Cox regression analysis in TCGA and GEO,epigenetic-related genes(ERGs)were identified by interacting those genes with EpiFactors,the enrichment analysis of ERGs also detected,then a prognostic signature was constructed by multivariate Cox regression analysis and validated.Results Six ERGs were screened,and the prognostic signature was constructed in our study,the AUC of the ROC was 0.722,and the calibration curve of 1-year,3-year,and 5-year were similar with the reality results,showed the signature had great prediction ability.Conclusion This study identified 6 ERGs(LBR,SMARCD3,ZNF532,MAPKAPK3,SFPQ,SIN3B),which are closely related to the prognosis of CRC.
作者 田琳琳 葛建顺 贾筱琴 路国涛 殷旭东 TIAN Linlin;GE Jianshun;JIA Xiaoqin;LU Guotao;YIN Xudong(Dalian Medical University,Dalian 116000;Institute of Digestive Diseases,Yangzhou University;Department of Oncology,the Affiliated Hospital of Yangzhou University,China)
出处 《胃肠病学和肝病学杂志》 CAS 2023年第6期613-618,共6页 Chinese Journal of Gastroenterology and Hepatology
基金 国家自然科学基金(81873867)。
关键词 结肠癌 表观遗传 预后模型 列线图 Colorectal cancer Epigenetic Prognostic signature Nomogram
  • 相关文献

参考文献1

二级参考文献61

  • 1Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, RebeloM, Parkin DM, Forman D, Bray F. Cancer incidence and mortalityworldwide: sources, methods and major patterns in GLOBOCAN2012. Int J Cancer 2015; 136: E359-E386 [PMID: 25220842 DOI:10.1002/ijc.29210].
  • 2Jung KW, Won YJ, Kong HJ, Oh CM, Lee DH, Lee JS. Prediction ofcancer incidence and mortality in Korea, 2014. Cancer Res Treat 2014;46: 124-130 [PMID: 24851103 DOI: 10.4143/crt.2014.46.2.124].
  • 3van Steenbergen LN, Elferink MA, Krijnen P, Lemmens VE,Siesling S, Rutten HJ, Richel DJ, Karim-Kos HE, Coebergh JW.Improved survival of colon cancer due to improved treatment anddetection: a nationwide population-based study in The Netherlands1989-2006. Ann Oncol 2010; 21: 2206-2212 [PMID: 20439339DOI: 10.1093/annonc/mdq227].
  • 4Quaglia A, Tavilla A, Shack L, Brenner H, Janssen-Heijnen M,Allemani C, Colonna M, Grande E, Grosclaude P, Vercelli M. Thecancer survival gap between elderly and middle-aged patients inEurope is widening. Eur J Cancer 2009; 45: 1006-1016 [PMID:19121578 DOI: 10.1016/j.ejca.2008.11.028].
  • 5Surgery for colorectal cancer in elderly patients: a systematicreview. Colorectal Cancer Collaborative Group. Lancet 2000; 356:968-974 [PMID: 11041397 DOI: 10.1016/S0140-6736(00)02713-6].
  • 6Potosky AL, Harlan LC, Kaplan RS, Johnson KA, Lynch CF. Age,sex, and racial differences in the use of standard adjuvant therapyfor colorectal cancer. J Clin Oncol 2002; 20: 1192-1202 [PMID:11870160].
  • 7Sundararajan V, Mitra N, Jacobson JS, Grann VR, Heitjan DF,Neugut AI. Survival associated with 5-fluorouracil-based adjuvantchemotherapy among elderly patients with node-positive coloncancer. Ann Intern Med 2002; 136: 349-357 [PMID: 11874307DOI: 10.7326/0003-4819-136-5-200203050-00007].
  • 8Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvantchemotherapy use after surgery for stage III colon cancer. J NatlCancer Inst 2001; 93: 850-857 [PMID: 11390534 DOI: 10.1093/jnci/93.11.850].
  • 9Aparicio T, Navazesh A, Boutron I, Bouarioua N, Chosidow D,Mion M, Choudat L, Sobhani I, Mentré F, Soulé JC. Half of elderlypatients routinely treated for colorectal cancer receive a substandardtreatment. Crit Rev Oncol Hematol 2009; 71: 249-257[PMID: 19131256 DOI: 10.1016/j.critrevonc.2008.11.006].
  • 10van Erning FN, van Steenbergen LN, Lemmens VE, Rutten HJ,Martijn H, van Spronsen DJ, Janssen-Heijnen ML. Conditionalsurvival for long-term colorectal cancer survivors in theNetherlands: who do best- Eur J Cancer 2014; 50: 1731-1739[PMID: 24814358 DOI: 10.1016/j.ejca.2014.04.009].

共引文献22

同被引文献10

引证文献1

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部